阿普斯特价格一览

Introduction: Apremilast is a phosphodiesterase inhibitor drug that works by blocking the effects of certain natural substances in the body that cause inflammation. It can be used to treat adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis. Apremilast is a drug that treats conditions such as psoriasis, mouth ulcers and arthritis, and there is a significant price difference between the brand-name version and generic versions.

Prices of Apremilast’s original and generic drugs

The original drug manufacturer is Celgene, a subsidiary of Bristol-Myers Squibb (BMS). It has not yet been launched in the country, and the specific price in the country cannot be known. The most common generic version of Apremilast is Apremilast produced by Glenmark in India. It comes in two specifications. The price of a box of 30mg*30 pills is about US$22, and the price of a box of 30mg*60 pills is about US$32.

The price of Apremilast drugs is for reference only. The price may change due to factors such as drug version, purchase channel, exchange rate changes, etc. Patients need to refer to the actual price. They can consult the hospital or pharmacy for specific drug prices.

Side effects of Apremilast

As a drug for treating autoimmune diseases, the side effects of Apremilast cannot be ignored. The most common side effects of Apremilast are gastrointestinal symptoms such as nausea, diarrhea and headache, with an incidence rate of more than 30%. In addition, it may also cause mild dry mouth, fatigue, insomnia and other uncomfortable reactions. More serious side effects include low mood, depressive symptoms, anxiety, suicidal tendencies, rash, hypotension, etc.

Use of Apremilast in Special Populations

Pregnant and lactating women

The potential effects of Apremilast on the fetus or infant are unknown, so pregnant women, women planning pregnancy, or lactating women should consult a doctor to weigh the potential benefits and risks of the drug before use.

Children

The safety and effectiveness of Apremilast in children under 18 years of age have not been established and therefore its use in children under 18 years of age is not recommended.

Elderly

In elderly subjects (65-85 years old), apremilast exposure (AUC) is approximately 13% higher than in younger subjects (18-55 years old), but dose adjustment is generally not required.

Patients with impaired hepatic function

When patients with moderate or severe hepatic impairment use Apremilast, the pharmacokinetics are not significantly affected, but they still need to be used with caution under the guidance of a doctor.

During the period of taking Apremilast, patients should undergo regular physical examinations and monitor weight, liver and kidney function and other indicators. If you experience unexplained weight loss or other abnormal symptoms, you should seek medical attention promptly.